Longeveron (NASDAQ: LGVN)/b) announced that additional Phase 2a clinical data analysis of its stem cell therapy in mild Alzheimer’s disease was accepted for a poster presentation at the 2026 Alzheimer’s Association International Conference (AAIC) in London, July 12-15, 2026.

The poster, titled “Laromestrocel in Mild Alzheimer’s Disease: Additional Phase 2a Clinical Data Analysis,” will be presented Monday, July 13, 2026, 7:30am–4:15pm BST. According to Longeveron, prior CLEAR MIND Phase 2a results supporting laromestrocel’s therapeutic potential were published in Nature Medicine in March 2025.